Immunotherapy: should we worry about immunosenescence?
Ageing and Cancer Research & Treatment · 2024
DOI: 10.70401/acrt.2024.104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ageing and Cancer Research & Treatment, 2024. Verfasst von Asli Özkan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Department of Medical Oncology, Leiden University Medical Center, Leiden 2333 ZA, The Netherlands. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.
Abstract (Originalsprache)
The global aging population is expected to experience a nofigure increase in cancer incidence, particularly among individuals aged 70 and older. At the same time, the extensive use of immune checkpoint inhibitors (ICIs) in cancer treatment raises questions about the influence of immunosenescence, the age-related decline in immune function, on treatment efficacy in older patients. Despite promising outcomes, resistance to immunotherapies and the occurrence of severe immune-related adverse events (irAEs) remain challenges. Limited research has explored the correlation between immunosenescence markers in peripheral blood and the tumour microenvironment (TME), frailty, and ICI response, and irAEs in older patients. This commentary explores the interrelationship between immunosenescence and immunotherapy in older and frail patients with cancer undergoing ICI therapy. Understanding the impact of immunosenescence on treatment response and irAEs, and identifying reliable biomarkers, is crucial for future research in geriatric oncology, as this will possibly facilitate patient stratification and personalized treatment approaches, ultimately improving patient outcomes while minimizing irAE-related risks.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Department of Medical Oncology, Leiden University Medical Center, Leiden 2333 ZA, The Netherlands.
- Department of Medical Oncology, Helse Førde, Svanehaugvegen 2, Førde 6812, Norway.
Förderung
- ZonMw
Zitieren
APA
Özkan, A., de Glas, N. A., & Portielje, J. E. A. (2024). Immunotherapy: should we worry about immunosenescence?. Ageing and Cancer Research & Treatment. https://doi.org/10.70401/acrt.2024.104
Vancouver
Özkan A, de Glas NA, Portielje JEA. Immunotherapy: should we worry about immunosenescence?. Ageing and Cancer Research & Treatment. 2024. doi:10.70401/acrt.2024.104
BibTeX
@article{zkan2024,
author = {Özkan, Asli and de Glas, Nienke A and Portielje, Johanneke E A},
title = {Immunotherapy: should we worry about immunosenescence?},
journal = {Ageing and Cancer Research & Treatment},
year = {2024},
doi = {10.70401/acrt.2024.104}
}
EUVIMED